Joseph A. Francisco

4.1k total citations · 3 hit papers
17 papers, 3.1k citations indexed

About

Joseph A. Francisco is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Immunology. According to data from OpenAlex, Joseph A. Francisco has authored 17 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Radiology, Nuclear Medicine and Imaging, 7 papers in Oncology and 5 papers in Immunology. Recurrent topics in Joseph A. Francisco's work include Monoclonal and Polyclonal Antibodies Research (14 papers), HER2/EGFR in Cancer Research (7 papers) and Toxin Mechanisms and Immunotoxins (5 papers). Joseph A. Francisco is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (14 papers), HER2/EGFR in Cancer Research (7 papers) and Toxin Mechanisms and Immunotoxins (5 papers). Joseph A. Francisco collaborates with scholars based in United States, Germany and Canada. Joseph A. Francisco's co-authors include Dana F. Chace, Peter D. Senter, Charles G. Cerveny, Damon L. Meyer, Clay B. Siegall, Alan F. Wahl, Svetlana O. Doronina, Brian E. Toki, Kim M. Kissler and Roger F. Zabinski and has published in prestigious journals such as Journal of Biological Chemistry, Blood and Nature Biotechnology.

In The Last Decade

Joseph A. Francisco

16 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate

2004 909 citations Kevin J. Hamblett, Peter D. Senter et al. Clinical Cancer Research profile →
Development of potent monoclonal antibody auristatin conjugates for cancer therapy

2003 903 citations Svetlana O. Doronina, Brian E. Toki et al. Nature Biotechnology profile →
cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

2003 668 citations Joseph A. Francisco, Charles G. Cerveny et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joseph A. Francisco United States	12	1.9k	1.8k	1.1k	489	415	17	3.1k
Dana F. Chace United States	15	1.9k 1.0×	1.8k 1.0×	1.1k 1.0×	482 1.0×	550 1.3×	22	3.1k
Charles G. Cerveny United States	16	2.7k 1.4×	2.4k 1.3×	1.4k 1.3×	575 1.2×	501 1.2×	26	4.1k
Svetlana O. Doronina United States	15	2.4k 1.3×	2.2k 1.2×	1.4k 1.3×	455 0.9×	366 0.9×	27	3.8k
Brian E. Toki United States	14	1.6k 0.8×	1.4k 0.8×	1.1k 1.0×	352 0.7×	325 0.8×	15	2.9k
Damon L. Meyer United States	28	2.9k 1.5×	3.0k 1.6×	1.7k 1.6×	597 1.2×	509 1.2×	40	4.9k
Clay B. Siegall United States	27	1.5k 0.8×	1.4k 0.8×	1.2k 1.1×	472 1.0×	1.2k 3.0×	60	3.4k
Pamela A. Trail United States	29	1.5k 0.8×	1.2k 0.7×	1.7k 1.6×	254 0.5×	474 1.1×	61	3.7k
Kerry Klussman United States	19	1.4k 0.7×	938 0.5×	792 0.7×	431 0.9×	1.8k 4.4×	37	3.4k
Russell J. Sanderson United States	13	1.1k 0.6×	1.0k 0.6×	884 0.8×	223 0.5×	190 0.5×	18	2.0k
Che‐Leung Law United States	36	1.7k 0.9×	1.5k 0.8×	1.6k 1.5×	668 1.4×	2.3k 5.6×	99	5.0k

Countries citing papers authored by Joseph A. Francisco

Since Specialization

Citations

This map shows the geographic impact of Joseph A. Francisco's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph A. Francisco with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph A. Francisco more than expected).

Fields of papers citing papers by Joseph A. Francisco

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph A. Francisco. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph A. Francisco. The network helps show where Joseph A. Francisco may publish in the future.

Co-authorship network of co-authors of Joseph A. Francisco

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph A. Francisco. A scholar is included among the top collaborators of Joseph A. Francisco based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph A. Francisco. Joseph A. Francisco is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Gordon, Kristine A., Brian E. Toki, Charles G. Cerveny, et al.. (2006). Lymphocyte Activation Antigen CD70 Expressed by Renal Cell Carcinoma Is a Potential Therapeutic Target for Anti-CD70 Antibody-Drug Conjugates. Cancer Research. 66(4). 2328–2337. 123 indexed citations

Senter, Peter D., Brian A. Mendelsohn, Brian E. Toki, et al.. (2004). Immunoconjugates comprised of drugs with impaired cellular permeability: A new approach to targeted therapy. Cancer Research. 64. 144–144. 2 indexed citations

Hamblett, Kevin J., Damon L. Meyer, Dana F. Chace, et al.. (2004). Effect of drug loading on the pharmacology, pharmacokinetics, and toxicity of an anti-CD30 antibody-drug conjugate. Cancer Research. 64. 144–144.

Law, Che‐Leung, Charles G. Cerveny, Kristine A. Gordon, et al.. (2004). Efficient Elimination of B-Lineage Lymphomas by Anti-CD20–Auristatin Conjugates. Clinical Cancer Research. 10(23). 7842–7851. 84 indexed citations

Cerveny, Charles G., Che‐Leung Law, Kevin J. Hamblett, et al.. (2004). The Anti-CD30 Monoclonal Antibody SGN-30 Inhibits Hodgkins Disease Growth and Sensitizes Cells to Established Chemotherapeutics.. Blood. 104(11). 2639–2639. 3 indexed citations

Hamblett, Kevin J., Peter D. Senter, Dana F. Chace, et al.. (2004). Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate. Clinical Cancer Research. 10(20). 7063–7070. 909 indexed citations breakdown →

Doronina, Svetlana O., Brian E. Toki, Michael Torgov, et al.. (2003). Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nature Biotechnology. 21(7). 778–784. 903 indexed citations breakdown →

Francisco, Joseph A., Charles G. Cerveny, Damon L. Meyer, et al.. (2003). cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 102(4). 1458–1465. 668 indexed citations breakdown →

McDonagh, Charlotte F., et al.. (2003). Improved Yield and Stability of L49-sFv−β-Lactamase, a Single-Chain Antibody Fusion Protein for Anticancer Prodrug Activation, by Protein Engineering. Bioconjugate Chemistry. 14(5). 860–869. 11 indexed citations

10.

Wahl, Alan F., Kerry Klussman, Jennifer Thompson, et al.. (2002). The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.. PubMed. 62(13). 3736–42. 167 indexed citations

11.

Francisco, Joseph A. & Clay B. Siegall. (1998). Single-Chain Immunotoxins Targeted to CD40 for the Treatment of Human B Lineage Hematologic Malignancies. Leukemia & lymphoma. 30(3-4). 237–245. 3 indexed citations

12.

Francisco, Joseph A., Susan L. Gawlak, & Clay B. Siegall. (1997). Construction, Expression, and Characterization of BD1-G28-5 sFv, a Single-chain Anti-CD40 Immunotoxin Containing the Ribosome-inactivating Protein Bryodin 1. Journal of Biological Chemistry. 272(39). 24165–24169. 20 indexed citations

13.

Francisco, Joseph A., Susan L. Gawlak, Michael M. Miller, et al.. (1997). Expression and Characterization of Bryodin 1 and a Bryodin 1-Based Single-Chain Immunotoxin from Tobacco Cell Culture. Bioconjugate Chemistry. 8(5). 708–713. 41 indexed citations

14.

Francisco, Joseph A., George J. Schreiber, Garvin L. Warner, et al.. (1997). In Vivo Efficacy and Toxicity of a Single-Chain Immunotoxin Targeted to CD40. Blood. 89(12). 4493–4500. 21 indexed citations

15.

Francisco, Joseph A., Lisa K. Gilliland, M. R. Stebbins, et al.. (1995). Activity of a single-chain immunotoxin that selectively kills lymphoma and other B-lineage cells expressing the CD40 antigen.. PubMed. 55(14). 3099–104. 33 indexed citations

16.

Francisco, Joseph A. & George Georgiou. (1994). The Expression of Recombinant Proteins on the External Surface of Escherichia coli. Annals of the New York Academy of Sciences. 745(1). 372–382. 32 indexed citations

17.

Francisco, Joseph A., Christos Stathopoulos, R. Anthony J. Warren, Douglas G. Kilburn, & George Georgiou. (1993). Specific Adhesion and Hydrolysis of Cellulose by Intact Escherichia coli Expressing Surface Anchored Cellulase or Cellulose Binding Domains. Nature Biotechnology. 11(4). 491–495. 94 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact